Benefit-driven approach

Added Values to our Pharmaceutical and Biotech sponsors

Medicine and Sciences	Operations	Regulatory and Access to market
IMPACTS
Quality of data: Lower variability and bias across readers	Simplified, automated and standardized seamless workflow	Quality of data presented to Health Authorities and Payers
Enhanced imaging criteria: Development of Advanced Imaging Biomarkers	Near real time information	Development of new Imaging Biomarkers that can themselves turn into additional claims.
Project management: Near real time information	Simplified reading process
	IT infrastructure for Data Mining
BENEFITS
Personalized diagnostics: Better evaluation of the drug candidate / new therapeutic strategy efficacy. Improved go/no go decisions	Time saving due to a reduction of administrative activities and better Management of Data workflow from sites to Central Data Base	More robust value dossier to support approval from Health Authorities whether fast track or standard processes
Increased reliability of the quality of the imaging data to support regulatory filings.	Reduction of missing, lost or incomplete data leading to stringer statistical power and reduction of number of patients to enroll	Supportive evidence to Pricing and reimbursement committees
Faster data allow better patient monitoring and coordination between sponsor and sites	Full transparency over project activities : near real time information, rapid feed –backs to the sites.	Direct access to retrospective data set to perform additional analysis for therapy assessment
Adaptive designs allowing less patients, faster data lock	Decentralized process (ie. Without central readings and adjudications) leads to immediate cost saving